在慢性脏病中使用内甲素受体对手
J David Smeijer1, Donald E Kohan2, Neeraj Dhaun3
1Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Nature reviews. Nephrology
|December 6, 2024
概括
内甲素受体对抗剂 (ERA) 通过减少白蛋白尿和保持功能,在治疗慢性病 (CKD) 中表现有前途. 优化ERA的使用需要仔细选择患者和剂量,以最大限度地减少副作用,如液体保留.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- 内甲素-1 (ET-1) 在生理学中起着关键作用,其过度表达有助于慢性病 (CKD) 病理生理学.
- 选择性内分泌素受体抗剂 (ERA) 向内分泌素A (ETA) 受体,在脏疾病的临床前和临床研究中显示出治疗潜力.
研究的目的:
- 审查目前对慢性病患者使用内甲素受体抗剂 (ERA) 的理解.
- 为了指导最佳,安全和有效的临床应用ERA在管理CKD.
主要方法:
- 对CKD中ERA的现有文献的审查,包括临床试验和临床前数据.
- 分析各种ERA的疗效和安全性概况,如阿特拉森坦,斯帕森坦和阿普罗西坦.
- 检查涉及ERA和其他药物,如SGLT2抑制剂的组合疗法.
主要成果:
- 选择性ETA ERAs,像阿特拉森坦,在2型糖尿病和CKD患者中减少了白蛋白尿和减缓功能下降.
- 像斯帕森坦这样的双重作用药物在IgA脏病中,在降低液体保留的情况下,保留了功能.
- 与ERA和SGLT2抑制剂的联合治疗增强了白色素尿减少和减轻了水分保留.
结论:
- 慢性脏病 (ERA) 是一种有价值的治疗类别,用于治疗慢性脏病 (CKD).
- 优化ERA治疗包括仔细选择患者和剂量策略,以平衡疗效并最大限度地减少水分保留和心力衰竭等不良影响.
- 新出现的数据支持使用新型ERA和组合疗法来改善CKD管理.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:25Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
477
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
477
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
581
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
581
01:22Heart Failure Drugs: Diuretics
340
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340